Kyverna Therapeutics (KYTX) Other Accumulated Expenses (2023 - 2026)

Kyverna Therapeutics has reported Other Accumulated Expenses for 4 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 71.94% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 71.94% YoY), and the FY2025 full-year result was $2.2 million, down 25.22% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.0 million, up from $2.2 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.0 million in Q1 2026, with the low at $1.2 million in Q2 2025.
• Historically, Other Accumulated Expenses has averaged $2.1 million across 4 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses retreated 25.22% — and 2026, when it jumped 71.94%.
• Kyverna Therapeutics' Other Accumulated Expenses stood at $1.8 million in 2023, then soared by 62.27% to $2.9 million in 2024, then dropped by 25.22% to $2.2 million in 2025, then soared by 39.15% to $3.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.0 million (Q1 2026), $2.2 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.